News and Announcements
After a $2 Billion buyout, Dr. Matt Joins AUM Biosciences’ Board of Directors
- Published August 12, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
AUM Biosciences (AUM), a Singapore-based company officially announced today the addition of Dr. Matt Devalaraja to its Board of Directors. AUM is focused on the development of innovative and affordable oncology medicines for cancers with high unmet medical need in Asia.
About Matt Devalaraja
Matt Devalaraja is the founder, Chief Scientific Officer and Head of Research and Development of Corvidia Therapeutics. Dr. Devalaraja is an immunologist with more than 20 years of experience in drug discovery and development across multiple therapeutic areas.
Prior to founding Corvidia, Dr. Devalaraja was Director of Emerging Innovations Unit at AstraZeneca, where he enabled multiple clinical studies and developed the core hypothesis of precision cardiovascular therapeutics that formed the basis for Corvidia spinout. He also was Head of Immunology Research, Pharmacokinetics and Toxicology groups at Human Genome Sciences, and was integral to the approval of Benlysta for Lupus and Raxibacumab for Anthrax.
Dr. Devalaraja started his career at Pfizer in Ann Arbor and brought forth the first biologic program for Pfizer’s Global Immunology portfolio. As Head of Biologics Discovery at Pfizer Ann Arbor, he initiated multiple programs across various therapeutic areas, including immunology and cardiovascular space, many of which are currently in various stages of clinical development. Currently, he is on the board of P2D Biosciences and is a founder of multiple startup biotech companies. Dr. Devalaraja received his Ph.D. from the University of Kentucky and completed his Post-Doctoral training at Vanderbilt University.
In June 2020, Corvidia Therapeutics was acquired by Novo Nordisk for a total deal value of 2.1 Billion USD.
“Dr. Devalaraja is a highly accomplished scientist and entrepreneur with an outstanding track record in bringing new drugs to market. We are delighted to have him join our Board and look forward to his guiding AUM’s growth” stated. Vishal Doshi, Chairman of the Board, AUM Biosciences.
“I look forward to working with and guiding AUM as they build their drug development pipeline and increase their global footprint in the oncology space” stated Dr. Matt Devalaraja.
About AUM Biosciences
AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. AUM is dedicated to revolutionizing the existing inefficient drug development paradigm by harnessing the power of precision medicine and digitalisation. AUM focuses on early stage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets. Led by a highly experienced management team with over 100 years of combined oncology drug development experience, AUM is disrupting the drug development paradigm by implementing a holistic approach to developing drugs. Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, pharmaceutical companies and clinicians globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year.
The company holds exclusive worldwide rights in all disease indications for 2 first-in-class composition of matter technologies. 1) MNK Inhibition and 2) Multi-Kinase Inhibition (PIM/PI3K/mTOR).
AUM001 is Phase II ready and AUM302 has a clear pathway to orphan drug designation. For more information, please visit www.aumbiosciences.com
Company Updates
Stop Leaving Millions on the Table: The Investor Secret You’re Missing!
In an Australian business landscape increasingly defined by volatility and intense competition for capital, the art of robust stakeholder relations has evolved beyond a mere governance checkbox. For founders, boards, and executive teams, the ability to genuinely inform and engage investors isn’t just about meeting disclosure requirements; it’s a strategic imperative that directly impacts capital […]
Ecosystems Over Exit: Callum Laing on Disrupting Small Business M&A
At Emergence Singapore, Callum Laing of Veblen Director Program presented a bold new vision for small business M&A: “Ecosystems Over Exit.” He shared how his Unity Group takes cash-generating businesses public, focusing on growth over immediate founder exit. Discover his unique approach, how interconnected ecosystems drive massive deal flow, and a three-step framework for any business to amplify reach and capital raising.
Report on the Impact of the Proposed Unrealised Capital Gains Tax on Investment in Key Sectors
A recent survey of investors and company leaders reveals significant concerns about the proposed Unrealised Capital Gains Tax (UCGT) in Australia. Over 84% indicate it would negatively impact investment in vital renewable energy, sustainability, and life science sectors, with 82% believing it would discourage long-term holdings. The report highlights the critical role of SMSF investors in early-stage funding and urges policymakers to reconsider the tax’s potential to stifle innovation and economic growth.
Backed By Leading Investment Groups and Family Offices
